Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In

Executive Summary

The growing use of risk management plans to mitigate risk in the post-marketing setting presents "potential harm to patients and the practice of medicine," FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said during a speech on drug safety at the Manhattan Institute in New York Nov. 13

You may also be interested in...



Outside Pressures Threaten FDA Effectiveness, Gottlieb Says

Payers are pushing for more comparative effectiveness studies, in part, because they know the more expensive and unwieldy studies will default to showing generics and branded drugs to be equal, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb

Outside Pressures Threaten FDA Effectiveness, Gottlieb Says

Payers are pushing for more comparative effectiveness studies, in part, because they know the more expensive and unwieldy studies will default to showing generics and branded drugs to be equal, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb

Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report

One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel